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Abstract
Background: Celiac disease may emerge at any age, but little is known of its appearance in elderly
people. We evaluated the prevalence of the condition in individuals over 55 years of age, and
determined the incidence of biopsy-proven celiac disease (CDb) and celiac disease including
seropositive subjects for anti-tissue transglutaminase antibodies (CDb+s).
Methods: The study based on prevalence figures in 2815 randomly selected subjects who had
undergone a clinical examination and serologic screening for celiac disease in 2002. A second
screening in the same population was carried out in 2005, comprising now 2216 individuals. Positive
tissue transglutaminase antibodies were confirmed with small bowel biopsy.
Results: Within three years the prevalence of CDb increased from 2.13 to 2.34%, and that of
CDb+s from 2.45 to 2.70%. Five new cases were found among patients previously seronegative;
two had minor abdominal symptoms and three were asymptomatic. The incidence of celiac disease
in 2002–2005 was 0.23%, giving an annual incidence of 0.08% in this population.
Conclusion: The prevalence of celiac disease was high in elderly people, but the symptoms were
subtle. Repeated screening detected five biopsy-proven cases in three years, indicating that the
disorder may develop even in the elderly. Increased alertness to the disorder is therefore
warranted.
Background
Celiac disease is a common disorder affecting more than
one percent of the population in the Western world [1].
Serologic screening enables detection of individuals with
atypical or subtle symptoms, or even symptomless cases
[2]. The condition is often assumed to involve children
and young adults. On the contrary, we recently revealed a
high number of both diagnosed and undetected celiac dis-
ease among elderly people [3]. It remains obscure whether
the number of undetected cases in the elderly is due to
diagnostic delay, or to the development of celiac disease
at an advanced age, or both. The question is important in
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contemplating whether celiac disease should be actively
sought in elderly people, and whether seronegativity
could exclude celiac disease once and for all. The aim of
this study was to show the current prevalence and inci-
dence of biopsy-proven celiac disease in individuals over
55 years of age. Given the high specificity of serum
endomysial (EmA) and tissue transglutaminase antibod-
ies (tTGA) for overt or forthcoming celiac disease, the fre-
quency of seropositivity was likewise investigated.
Methods
The original study population comprised 4272 randomly
selected individuals born in the years 1946–50, 1936–40
and 1926–30; the study sample was representative of the
general population in the respective age groups. Alto-
gether 2815 (66%) consented to participate in the original
study. Their data were collected for a 10-year research
project on Ageing and well-being (Good Ageing in the
Lahti region = GOAL) [4]. Sera were collected in 2002,
and tested for celiac disease antibodies in 2004. At that
time, the number of clinically detected celiac disease cases
was evaluated, and new seropositive cases underwent
small intestinal biopsy for confirmation of celiac disease.
The Amsterdam criteria were applied in the diagnosis of
the condition [5]. In the first population screening in
2002 the frequency of diagnosed celiac disease cases was
0.89%, that of screen-detected 1.24% and that of biopsy-
proven cases together with cases seropositive without his-
tological confirmation of the disorder 2.45%; these data
have been published elsewhere [3].
In 2005, all eligible patients were asked to undergo a new
serologic testing. Of the previously tested 2815 patients,
2216 consented. Again, clinically detected celiac disease
cases were scrutinized. All sera were tested for IgA class
tTGA; positive samples were further tested for IgA class
EmA. IgA class tTGA were detected by enzyme-linked
immunosorbent assay (Celikey, Phadia, Freiburg, Ger-
many) and the limit of positivity was 5 arbitrary units; IgA
class EmA were detected by an indirect immunofluores-
cence method using human umbilical cord as antigen; a
dilution of 1:³5 was considered positive [6].
All tTGA-positive patients without previous diagnosis of
celiac disease were offered upper gastrointestinal endos-
copy (irrespective of the EmA titre); four small intestinal
biopsies were taken form the distal part of the duodenum
and stained with hematoxylin-eosin. The diagnosis of
celiac disease was based on typical lesion in small intesti-
nal mucosa.
In the prevalence estimations, subjects with previously
detected celiac disease and new biopsy-proven cases
found by clinically or screening were included; they are
defined in this report as biopsy-proven celiac disease
(CDb). The combined prevalence of biopsy-proven and
seropositive cases included in addition individuals with
positive tTGA but no histological verification of celiac dis-
ease (CDb+s).
The incidence of biopsy-proven celiac disease (CDb) was
calculated in the 2216 subjects who were tested both in
2002 and 2005, and those seropositive without histologi-
cal confirmation were added in the combined incidence
figures (CDb+s), as defined in the prevalence figures.
Screening of New Cases
In the original on Ageing and well-being project, there
were 199 individuals whose sera were not available in
2002, but consented to screening in 2005. The prevalence
of CDb and CDb+s in this group was estimated separately.
The study was accepted by the Ethical committee of Päijät-
Häme Central Hospital, and written informed consent
was obtained from all participants.
Statistical Analysis
Prevalence figures were calculated with 95% confidence
intervals.
Results
In the first evaluation, 61 had had been diagnosed with
celiac disease (one additional case was found upon re-
examination of the case records after the first publication)
[3]. All 61 were alive in 2005, and were thus included in
the new prevalence data.
Of the 2216 individuals proving seronegative in the first
examination, six had undergone positive seroconversion
and five had biopsy-proven celiac disease (Marsh III); of
these five new cases two reported minor abdominal com-
plaints and three were asymptomatic. Thus, within three
years, 0.23% developed celiac disease (CDb) and 0.24%
underwent seroconversion (CDb+s). The values of IgA
tTGA antibodies and EmA in the five patients with newly
detected celiac disease are depicted in Table 1. The small
bowel biopsy findings in patients with the lowest positive
tTGA antibodies are shown in Figures 1 and 2. One of the
five subjects (patient 4, Table 1) had immunosuppressive
treatment (corticosteroids) upon the first and second
screening. In 2005 the prevalence of celiac disease (CDb)
was 2.34% in subjects aged 55 or more, and the frequency
of biopsy-proven and seropositive individuals (CDb+s)
2.70% (Table 2).
Of the 199 who underwent serologic screening for the first
time in 2005, five had positive IgA tTGA antibodies and
four positive EmA; three had villous atrophy compatible
with celiac disease; biopsy was not possible in one who
had moved away, and another subject declined due toBMC Gastroenterology 2009, 9:49 http://www.biomedcentral.com/1471-230X/9/49
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serious heart disease. Thus the frequency of celiac disease
was 1.5% (3/199), and when seropositives were included,
2.5% (5/199).
Discussion
We have previously shown that the prevalence of celiac
disease was higher in the elderly than what has been
reported in the Finnish population among adolescents
(1.5%)[7] or adults (2.0%) [8]. This difference might be
due to diagnostic delay, which would increase the preva-
lence of the disease by time; the mortality of patients is
low and comparable to that in the general population in
Finland [9]. Nevertheless, from 2002 to 2005, the preva-
lence of biopsy-proven celiac disease (CDb) in this age
group increased from 2.13% to 2.34%, and the combined
prevalence of disease and seropositivity (CDb+s) from
2.45% to 2.70%. Such a combination makes sense: serop-
ositivity for these specific antibodies in the absence of vil-
lous atrophy often indicates early developing celiac
disease [10], and seropositive without villous atrophy
may even benefit of dietary treatment [11].
There was a significant increase in the tTGA values in the
five subjects who underwent seroconversion and were
subsequently found to have biopsy proven coeliac disease
(Table 1). This implies that there occurred a true serocon-
version, though we did not have the opportunity to test
again the original sera. It was also notable that the biopsy
showed unequivocal villous atrophy and crypt hyperpla-
sia even in the two patients with the lowest positive tTGA
levels, shown in Figure 1 and 2.
It is not excluded that some of the five patients had had
seronegative celiac disease and became seropositive later.
On the other hand, there is some evidence that elderly
people with newly detected celiac disease rather become
Table 1: Serum Tissue Transglutaminase (tTGA) and Endomysial Antibody (EmA) Levels in the Five New Cases Who Underwent 
Positive Seroconversion and Were Found to Have Biopsy-Proven Celiac disease.
Gender, age (years), (by the time of diagnosis) Screening in 2002 Screening in 2005
tTGA (Units) EmA (titre) tTGA (Units) EmA (titre)
1: Male, 67 0.1 Not done 54.6 1:500
2: Female, 55 1.1 Not done 9.1 1:200
3: Male, 65 0.8 Not done 9.5 1:100
4: Female, 75 2.7 Not done 6.0 1:5a
5: Male, 66 0 Not done 7.1 0b
Reference Values for tTGA ³ 5 Units and for EmA 1:³5.
a Small bowel mucosal villous morphology is shown in Figures 1 and b 2
Table 2: Prevalence and Incidence of Celiac Disease (CD) and Seropositivity for IgA Class Tissue Transglutaminase (tTGA) and 
Endomysial (EmA) Antibodies in Patients Aged Over 55 Years.
Year, total 
population
Procedure Number 
clinically 
detected
tTGA positive 
in screening
EmA positive in 
screening
Biopsy-proven 
cases in 
screening
Overall 
frequency of 
biopsy proven 
CD
Patients with 
CD and tTGA 
seropositive 
individuals
2002, 2815 Serum sampling
2004, 2815 Recording of 
detected CD. 
First serologic 
analysis
25 48 43 35 60 69a
2005, 2216 Recording of 
detected CD. 
Second 
serologic 
screening
1645 b 67
Overall 
prevalence, N = 
2815
0.92% (26/2815) 1.92%
(54/2815)
1.70% (47/2815) 1.42%
(40/2815)
2.34%
(66/2815)
2.70%
(76/2815)
95% confidence 
intervals
0.57–1.27% 1.41–2.43% 1.22–2.18% 0.98–1.86% 1.78–2.90% 2.10–3.30%
a Four seropositive were found to have celiac disease between 2002–2004
bThe incidence of celiac disease 2002–2005 was 0.23% (5/2216)BMC Gastroenterology 2009, 9:49 http://www.biomedcentral.com/1471-230X/9/49
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seronegative by time [12]. This also means that the true
frequency of celiac disease may be even higher than
reported here.
Murray et al. [13] found that the incidence rates of celiac
disease increased with age. A low index of suspicion by a
physician may lead to diagnostic delay in recognition or
to a distraction to other disorders. Apart from better diag-
nostics, a true increase in incidence may also occur [14].
We showed for the first time that the frequency of celiac
disease was indeed increasing in elderly people, where
clinically detected cases were recorded, and serologic
screening has been carried out twice. The increase was
thus not due to better diagnostics. Finland is considered
genetically homogeneous, and there is no reason to
believe that the frequency of celiac disease would be
higher in Lahti region than in Finland in general.
The incidence of 0.23% during the study period implies
that celiac disease may develop even at an advanced age.
This again would imply that serologic testing should be
repeated. Admittedly, the number of new cases was to low
for any far-reaching conclusions. On the other hand, the
annual incidence of about 0.1% indicates that the number
of new cases may be 1% in 10 years. This percentage has
in fact been achieved in many population screening stud-
ies. We would further emphasize that this incidence figure
has been found in the general population with no suspi-
cion of celiac disease, and with originally a high number
of detected cases. The frequency of detected celiac disease
in our general population is as high as 0.45% [15]. It is
subject for further studies to establish whether the preva-
lence and incidence figures for celiac disease are even
higher in elderly people belonging to the risk groups for
the disease. For comparison, in relatives with celiac dis-
ease the incidence of new cases has been 1.7–4.5% within
7–12 years [16-18].
In those 199 screened for the first time, the prevalence of
biopsy-proven celiac disease (CDb) was 1.5% (3/199),
and when tTGA seroposives are included (CDb+s), 2.5%.
These percentages are comparable to those detected in the
main prospective study, supporting its results.
Earlier studies indicate that undiagnosed celiac disease
may generate significant problems in the elderly. Freeman
observed in his series of 30 celiac disease patients diag-
nosed over age 60 that they had suffered from many
symptoms and had altogether 14 malignant conditions
[19]. Hankey and Holmes [20] showed the diagnostic
delay in the elderly to be considerable: 15 out the 35 aged
60 years or over had attended physicians for an average of
28 years with different complaints before the diagnosis.
Their patients evinced good compliance with a gluten-free
diet, and subsequently a significant improvement in their
symptoms and signs. Similarly, Lurie et al. [21] found a
significant lack in diagnosis, and a varied spectrum of
manifestations in celiac patients diagnosed after the age of
60.
Conclusion
In conclusion, the prevalence of celiac disease proved to
be high in elderly people. Increased alertness and the free
employment of serologic screening tests are warranted.
One seronegative test result does not exclude forthcoming
celiac disease. Our serial screening in the same population
indicated that seropositivity and the disease may also
Small-bowel biopsy sample of the patient who underwent  positive seroconversion (Patient 4 in Table 1) Figure 1
Small-bowel biopsy sample of the patient who under-
went positive seroconversion (Patient 4 in Table 1).
Small-bowel biopsy sample of the patient who underwent  positive seroconversion (Patient 5 in Table 1) Figure 2
Small-bowel biopsy sample of the patient who under-
went positive seroconversion (Patient 5 in Table 1).Publish with BioMed Central    and   every 
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appear later in life. This should be taken into account
when considering celiac disease case finding and screen-
ing studies.
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